Go Pro
→ Elon Musk to Trigger Next AI Wave on November 11th? (From Brownstone Research) (Ad)tc pixel
NASDAQ:ARGX

argenex Q1 2026 Earnings Report

argenex logo
$984.39 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$1,000.61 +16.22 (+1.65%)
As of 07:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

argenex EPS Results

Actual EPS
$5.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

argenex Revenue Results

Actual Revenue
$1.31 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

argenex Announcement Details

Quarter
Q1 2026
Date
3/31/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

argenex Earnings Headlines

argenex SE (NASDAQ:ARGX) Receives Average Recommendation of "Moderate Buy" from Brokerages
September 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31012021
argenex (NASDAQ:ARGX) Rating Increased to Buy at Wall Street Zen
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005629
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
September 14 at 1:00 AM  |  Stansberry Research (Ad)
Wedbush Reaffirms "Outperform" Rating for argenex (NASDAQ:ARGX)
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003941
argenex (NASDAQ:ARGX) Sets New 52-Week High - Here's What Happened
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003206
Argenx has delivered 18 consecutive quarters of sales growth but is the biotech stock still underrated?
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/argenx-has-delivered-18-consecutive-quarters-of-sales-growth-but-is-the-biotech-stock-still-underrated/ar-AA2bp8b5
See More argenex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like argenex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on argenex and other key companies, straight to your email.

About argenex

argenx SE is a global biopharmaceutical company focused on developing and commercializing antibody-based medicines for patients with severe autoimmune diseases. The company’s research is centered on its antibody engineering technologies, including the SIMPLE Antibody platform and NHance technology, which are designed to identify and enhance therapeutic antibodies.

argenx’s leading product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce disease-causing immunoglobulin G antibodies. VYVGART and its subcutaneous formulation, VYVGART Hytrulo, are used in the treatment of generalized myasthenia gravis in various markets. The products have also expanded into chronic inflammatory demyelinating polyneuropathy, subject to regulatory approvals in applicable jurisdictions. The company is studying efgartigimod in additional autoimmune conditions.

Founded in 2008, argenx is headquartered in Ghent, Belgium, and maintains operations in the United States and other international markets. Its medicines are available in multiple geographies through regulatory approvals and commercial partnerships. Tim Van Hauwermeiren serves as the company’s chief executive officer.

View argenex Profile
Earnings Tools